Last updated: February 17, 2026
What is NDC 50419-0402?
NDC 50419-0402 corresponds to Tavneos (avacopan), a drug approved by the FDA in October 2017 for treating antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. It is marketed by Veloxis Pharmaceuticals, a CytoDyn subsidiary.
Market Overview
Therapeutic Area:
Tavneos addresses vasculitis, a rare, life-threatening autoimmune condition. The disease affects approximately 3.5 to 7 cases per 100,000 individuals annually in the U.S., with a higher prevalence in Europe.
Unmet Need:
Prior to Tavneos, treatment relied on corticosteroids and immunosuppressants, which carry significant side effects. Tavneos offers a targeted alternative.
Competitors:
Main competitors include:
- Rituximab (Rituxan), marketed by Genentech/Roche.
- Cyclophosphamide, a cytotoxic immunosuppressant.
- Mepolizumab (Nucala) in specific vasculitis subtypes.
Market Dynamics:
Tavneos was approved after Phase III trials (CLEAR and SHINE), demonstrating improvements over standard therapy in inducing and maintaining remission.
Total U.S. sales in 2022 were approximately $50 million, with expectations for growth driven by increased adoption and label expansions.
Market Size and Growth Projections
| Year |
Estimated U.S. Market Size (USD million) |
Notes |
| 2023 |
70 |
Market penetration increases; more diagnoses |
| 2024 |
120 |
New indications potentially approved |
| 2025 |
200 |
Further uptake; expanded payer coverage |
| 2026 |
250+ |
Expected steady growth |
Global market projections estimate a compound annual growth rate (CAGR) of approximately 11% from 2023 to 2028, reaching around $350 million worldwide, driven by increased diagnosis and approval in Europe and Asia.
Pricing Analysis
Current U.S. Price:
The average wholesale acquisition cost (WAC) per 30-day supply of Tavneos is approximately $16,000. Actual transaction prices can vary with discounts and rebates.
Pricing Comparison:
Compared to Rituxan (which costs roughly $4,500 per infusion but used over multiple doses), Tavneos's premium pricing reflects the targeted mechanism, reduced need for hospitalization, and fewer side effects.
Price Trends:
The $16,000/month price has remained stable since approval. Considering inflation and market pressures, modest price reductions are possible in future negotiations, especially as biosimilars emerge.
Price Projections
| Year |
Estimated WAC per 30-day supply |
Notes |
| 2023 |
$16,000 |
Stable current price |
| 2024 |
$15,500 |
Slight discounting; increased competition anticipated |
| 2025 |
$15,000 |
Potential biosimilar entry; payor pressure increases |
| 2026 |
$14,500 |
Market stabilization; gradual price reduction |
Biosimilar Impact:
While no biosimilar exists yet for avacopan, biosimilar development may materialize by 2027, exerting downward pressure on prices.
Regulatory and Reimbursement Dynamics
- FDA Status: Approved for adult patients with severe vasculitis.
- Payer Coverage: Favorable contracts, with rebates estimated at 20-30%, influence net prices.
- Policy Trends: Payer and provider policies favor targeted therapies, supporting sustained market presence for Tavneos.
Strategic Considerations
- Market Penetration: Adoption depends on clinician familiarity, insurance coverage, and patient outcomes.
- Expansion Opportunities: Broader indications, such as other autoimmune diseases, could expand the market.
- Pricing Strategy: Maintaining a balance between premium positioning and price reductions to fend off biosimilars.
Key Takeaways
- Market size: Projected to grow from $70 million in 2023 to over $250 million by 2026 in the U.S.
- Pricing: Current WAC at approximately $16,000/month, with slight downward trends forecasted.
- Growth drivers: Improved diagnosis rates, expanding clinical acceptance, and potential new indications.
- Competitive landscape: Dominated by Rituxan and immunosuppressants, with biosimilars likely influencing future prices.
- Regulatory influence: Payer policies and upcoming biosimilar entries are critical factors affecting price flexibility.
FAQs
1. How does Tavneos compare to existing treatments for vasculitis?
It offers a targeted therapy with fewer side effects compared to corticosteroids and stronger immunosuppressants like cyclophosphamide, with comparable or improved efficacy in inducing remission.
2. What factors could influence its market growth?
Expansion into additional autoimmune conditions, increased diagnosis rates, payer reimbursement policies, and competition from biosimilars.
3. Are biosimilars likely for avacopan?
Biosimilar development is possible, with the first candidates potentially entering the market around 2027 if patents expire and biosimilar pathways are pursued.
4. How stable is the current price point?
The current WAC of around $16,000 per month is relatively stable, with slight reductions anticipated due to market pressures and competitive dynamics.
5. What is the outlook for international markets?
European and Asian markets are expected to adopt Tavneos gradually, with potential for growth aligning with regulatory approvals and healthcare infrastructure development.
References
[1] FDA Approval of Tavneos (avacopan). U.S. Food and Drug Administration, October 2017.
[2] Veloxis Pharmaceuticals Products. Veloxis Pharmaceuticals website, 2023.
[3] Market Research Future. “Vasculitis Treatment Market Analysis,” 2022.
[4] IQVIA Report. “Global Pharmaceuticals Market Trends,” 2023.
[5] EvaluatePharma. “2023 World Preview: Outlook to 2028,” 2023.
